Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Tisch Cancer Institute at Mount Sinai Medical Center, New York

Roswell Park Cancer Institute, Buffalo

University of Rochester Medical Center, Rochester

Fox Chase Cancer Center, Philadelphia

Georgetown University, Washington D.C.

University of Maryland, Baltimore

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Virginia Oncology Associates, Norfolk

University of North Carolina at Chapel Hill, Chapel Hill

Medical University of South Carolina, Charleston

University of Florida, Gainesville

Vanderbilt-Ingram Cancer Center, Nashville

Ohio State University Comprehensive Cancer Center, Columbus

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

IU Health Central Indiana Cancer Center, Indianapolis

Community Regional Cancer Care, Indianapolis

Community Healthcare System, Munster

IU Health Goshen Center for Cancer Care, Goshen

Henry Ford Health System, Detroit

University of Minnesota, Minneapolis

Washington University: Siteman Cancer Center, St Louis

GU Cancer Research Network, LLC, Omaha

Huntsman Cancer Institute University of Utah, Salt Lake City

University of Arizona at Dignity Health St. Joseph's, Phoenix

University of New Mexico Cancer Center, Albuquerque

University of Southern California, Los Angeles

City of Hope Comprehensive Cancer Center, Duarte

The John Theuer Cancer Center at Hackensack University Medical Center, Hackensack